SEC Filing Summary for Acumen Pharmaceuticals, Inc.

This filing details transactions by John A. Stalfort III, a director at Acumen Pharmaceuticals, Inc. (ABOS). On June 3, 2026, Stalfort was granted 35,500 shares of Common Stock as a restricted stock unit (RSU) award, which will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, contingent upon continuous service. Additionally, an option to buy 53,250 shares of Common Stock was granted, also vesting under the same conditions. The option has an exercise price of $2.29 and an expiration date of June 3, 2036. Following these transactions, Stalfort directly holds 220,624 shares of Common Stock and 53,250 shares underlying the stock option.